Nuuvera Signs Letter of Intent to Acquire GMP-Certified Lab In Spain

TORONTOJan. 24, 2018 /CNW/ – Nuuvera Inc. (“Nuuvera”) (TSXV:NUU), is pleased to announce that it has signed a Letter of Intent (“LOI”) with Medalchemy S.L. (“Medalchemy”) to acquire a majority interest in its fully-licensed, GMP certified laboratory located in Alicante, Spain.

Medalchemy’s laboratory, located on the premises of the University of Alicante, has a decade of experience in the production and extraction of active pharmaceutical ingredients (“APIs”).

Nuuvera has also signed an LOI with Canamo y Fibra Naturales, S.L. (“CAFINA”), also based in Alicante.

Nuuvera will acquire a 30% interest in CAFINA, and intends to purchase cultivated cannabis products from the company as well as hemp to be used in CBD extraction. Nuuvera and CAFINA will also enter into a JV agreement, whereby CAFINA will have a minority interest in the Nuuvera’s subsidiary that controls Medalchemy.

“These anticipated investments will greatly enhance Nuuvera’s operational capacity to produce premium quality cannabis products, and our ability to supply the European market with medicinal cannabis,” said Lorne Abony, Chief Executive Officer of Nuuvera.

Nuuvera expects to announce a Final Agreement with both parties in the very near future.

“We have quickly established Nuuvera as a strong presence in the European and international medical cannabis market, with a presence in GermanyItaly and now Spain“, said Abony . “Europe comprises hundreds of millions of potential patients and consumers and also adheres to the highest grow and production standards. Our engagement in Europe complements Nuuvera’s market presence in Canada.”

About Nuuvera

Nuuvera is a global cannabis company founded on Canadian principles, and built with the whole world in mind. Nuuvera is currently working with partners in GermanyIsrael and Italy, and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets. Through its subsidiaries, ARA – Avanti Rx Analytics Inc. and Avalon Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its “letter to build” approval.

For more information on Nuuvera, please visitwww.nuuvera.com

Related Posts

Subscribe

Stay up to date with the latest news